[1] ABDEL-RAHMAN O. Systemic therapy for hepatocellular carcinoma (HCC):From bench to bedside[J]. J Egypt Natl Canc Inst, 2013, 25(4):165-171.
[2] WANG L, YAO M, DONG Z, et al. Circulating specific biomarkers in diagnosis of hepatocellular carcinoma and its metastasis monitoring[J]. Tumour Biol, 2014,35(1):9-20.
[3] BROWN J M. Vasculogenesis:A crucial player in the resistance of solid tumours to radiotherapy[J]. Br J Radiol, 2014,87(1035):20130686.
[4] DEMIR R, ABA A, HUPPERTZ B. Vasculogenesis and angiogenesis in the endometrium during menstrual cycle and implantation[J]. Acta Histochem, 2010,112(3):203-214.
[5] CHEN Y S, CHEN Z P. Vasculogenic mimicry:A novel target for glioma therapy[J]. Chin J Cancer, 2014, 33(2):74-79.
[6] SEFTOR R E, HESS A R, SEFTOR E A, et al. Tumor cell vasculogenic mimicry:From controversy to therapeutic promise[J]. Am J Pathol, 2012,181(4):1115-1125.
[7] MANIOTIS A J, FOLBERG R, HESS A, et al. Vascular channel formation by human melanoma cells in vivo and in vitro:Vasculogenic mimicry[J]. Am J Pathol, 1999,155(3):739-752.
[8] MCDONALD D M, MUNN L, JAIN R K. Vasculogenic mimicry:How convincing, how novel, and how significant[J]. Am J Pathol, 2000,156(2):383-388.
[9] FOLBERG R, ARBIEVA Z, MOSES J, et al. Tumor cell plasticity in uveal melanoma:Microenvironment directed dampening of the invasive and metastatic genotype and phenotype accompanies the generation of vasculogenic mimicry patterns[J]. Am J Pathol, 2006, 169(4):1376-1389.
[10] BASU G D, LIANG W S, STEPHAN D A, et al. A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cells[J]. Breast Cancer Res, 2006,8(6):R69.
[11] MAQUART F X, MONBOISSE J C. Extracellular matrix and wound healing[J]. Pathol Biol (Paris), 2014, 62(2):91-95.
[12] MOUW J K, OU G, WEAVER V M. Extracellular matrix assembly:A multiscale deconstruction[J]. Nat Rev Mol Cell Biol, 2014,15(12):771-785.
[13] KEELY P J. Mechanisms by which the extracellular matrix and integrin signaling act to regulate the switch between tumor suppression and tumor promotion[J]. J Mammary Gland Biol Neoplasia, 2011,16(3):205-219.
[14] GUO J Q, ZHENG Q H, CHEN H, et al. Ginsenoside Rg3 inhibition of vasculogenic mimicry in pancreatic cancer through downregulation of VEcadherin/EphA2/MMP9/MMP2 expression[J]. Int J Oncol, 2014,45(3):1065-1072.
[15] LU X S, SUN W, GE C Y, et al. Contribution of the PI3K/MMPs/Ln-5gamma2 and EphA2/FAK/Paxillin signaling pathways to tumor growth and vasculogenic mimicry of gallbladder carcinomas[J]. Int J Oncol, 2013,42(6):2103-2115.
[16] GIANNOTTA M, TRANI M, DEJANA E. VE-cadherin and endothelial adherens junctions:Active guardians of vascular integrity[J]. Dev Cell, 2013,26(5):441-454.
[17] LIU R, CAO Z, TU J, et al. Lycorine hydrochloride inhibits metastatic melanoma cell-dominant vasculogenic mimicry[J]. Pigment Cell Melanoma Res, 2012,25(5):630-638.
[18] LIU T, SUN B, ZHAO X, et al. HER2/neu expression correlates with vasculogenic mimicry in invasive breast carcinoma[J]. J Cell Mol Med, 2013,17(1):116-122.
[19] CHEN L X, SUN B C, LI X R, et al. Overexpression of the receptor tyrosine kinase EphA2 in choroidal melanoma:Correlation with vesculogenic mimicry and prognosis[J]. Chin J Ophthalmop(中华眼科杂志), 2012,48(11):985-990.
[20] WANG W, LIN P, SUN B, et al. Epithelial-mesenchymal transition regulated by EphA2 contributes to vasculogenic mimicry formation of head and neck squamous cell carcinoma[J]. Biomed Res Int, 2014:803914.
[21] ZHANG J T, SUN W, ZHANG W Z, et al. Norcantharidin inhibits tumor growth and vasculogenic mimicry of human gallbladder carcinomas by suppression of the PI3-K/MMPs/Ln-5gamma2 signaling pathway[J]. BMC Cancer, 2014,14:193.
[22] HENDRIX M J, SEFTOR E A, MELTZER P S, et al. Expression and functional significance of VE-cadherin in aggressive human melanoma cells:Role in vasculogenic mimicry[J]. Proc Natl Acad Sci USA, 2001, 98(14):8018-8023.
[23] KUMAR V, GABRILOVICH D I. Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment[J]. Immunology, 2014,143(4):512-519.
[24] RAJA R, KALE S, THORAT D, et al. Hypoxia-driven osteopontin contributes to breast tumor growth through modulation of HIF1alpha-mediated VEGF-dependent angiogenesis[J]. Oncogene, 2014, 33(16):2053-2064.
[25] LIANG X, XU F, MA C, et al. VEGF Signal system:The application of antiangiogenesis[J]. Curr Med Chem, 2014, 21(7):894-910.
[26] KIRSCHMANN D A, SEFTOR E A, HARDY K M, et al. Molecular pathways:Vasculogenic mimicry in tumor cells:Diagnostic and therapeutic implications[J]. Clin Cancer Res, 2012,18(10):2726-2732.
[27] DU J, SUN B, ZHAO X, et al. Hypoxia promotes vasculogenic mimicry formation by inducing epithelial-mesenchymal transition in ovarian carcinoma[J]. Gynecol Oncol, 2014, 133(3):575-583.
[28] TANG N N, ZHU H, ZHANG H J, et al. HIF-1alpha induces VE-cadherin expression and modulates vasculogenic mimicry in esophageal carcinoma cells[J]. World J Gastroenterol, 2014,20(47):17894-17904.
[29] SUN W, FAN Y Z, ZHANG W Z, et al. A pilot histomorphology and hemodynamic of vasculogenic mimicry in gallbladder carcinomas in vivo and in vitro[J]. J Exp Clin Cancer Res, 2011, 30(1):46-57.
[30] YAO X H, PING Y F, BIAN X W. Contribution of cancer stem cells to tumor vasculogenic mimicry[J]. Protein Cell, 2011,2(4):266-272.
[31] SCULLY S, FRANCESCONE R, FAIBISH M, et al. Transdifferentiation of glioblastoma stem-like cells into mural cells drives vasculogenic mimicry in glioblastomas[J]. J Neurosci, 2012,32(37):12950-12960.
[32] MIRSHAHI P, RAFII A, VINCENT L, et al. Vasculogenic mimicry of acute leukemic bone marrow stromal cells[J]. Leukemia, 2009, 23(6):1039-1048.
[33] VALYI-NAGY K, KORMOS B, ALI M, et al. Stem cell marker CD271 is expressed by vasculogenic mimicry-forming uveal melanoma cells in three-dimensional cultures[J]. Mol Vis, 2012,18(60-65):588-592.
[34] LIM J, THIERY J P. Epithelial-mesenchymal transitions:Insights from development[J]. Development, 2012,139(19):3471-3486.
[35] JING Y, CUI D, GUO W, et al. Activated androgen receptor promotes bladder cancer metastasis via Slug mediated epithelial-mesenchymal transition[J]. Cancer Lett, 2014,348(1-2):135-145.
[36] YANG Z, SUN B, LI Y, et al. ZEB2 Promotes vasculogenic mimicry by TGF-beta1 induced epithelial-to-mesenchymal transition in hepatocellular carcinoma[J]. Exp Mol Pathol, 2015,98(3):352-359.
[37] XIA H, CHEUNG W K, SZE J, et al. miR-200a regulates epithelial-mesenchymal to stem-like transition via ZEB2 and beta-catenin signaling[J]. J Biol Chem, 2010, 285(47):36995-37004.
[38] FANG X, CAI Y, LIU J, et al. Twist2 contributes to breast cancer progression by promoting an epithelial-mesenchymal transition and cancer stem-like cell self-renewa[J]. Oncogene, 2011,30(47):4707-4720.
[39] MIYAZAKI S, KIKUCHI H, LINO L, et al. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts[J]. Int J Cancer, 2014,135(2):295-307.
[40] HANNA S C, KRISHNAN B, BAILEY S T, et al. HIF1alpha and HIF2alpha independently activate SRC to promote melanoma metastases[J]. J Clin Invest, 2013,123(5):2078-2093.
[41] MENG J, SUN B, ZHAO X, et al. Doxycycline as an inhibitor of the epithelial-to-mesenchymal transition and vasculogenic mimicry in hepatocellular carcinoma[J]. Mol Cancer Ther, 2014,13(12):3107-3122.
[42] CHIABLAEM K, LIRDPRAPAMONGKOL K, KEERATICHAMROEN S, et al. Curcumin suppresses vasculogenic mimicry capacity of hepatocellular carcinoma cells through STAT3 and PI3K/AKT inhibition[J]. Anticancer Res, 2014,34(4):1857-1864.
[43] ZHENG A H, ZHANG W D, WANG Z P, et al. Research on the effect and mechanism of polypeptide extract from scorpion venom combined with 5-fluorouracil on vasculogenic mimicry of H22 hepatoma[J]. Chin J Integr Tradit West Med(中国中西医结合杂志), 2013,33(4):492-496.